CG Oncology, Inc. Common stock

CG Oncology, Inc. Common stock

CGON·NASDAQ

$54.42

-0.85%
HealthcareBiotechnology

CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

At a Glance

Live Snapshot
Market Cap$4.80B
EPS-2.0800
P/E Ratio-26.16
Earnings Date08/07/2026

No Dividend Yield Data

CGON has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

CGON has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

CGON has not reported any net dividends paid values in the available annual periods.

CG Oncology, Inc. Common stock

CG Oncology, Inc. Common stock Dividend History

CGON · NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

CGON Dividend Payment History

CGON · NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
cgon

CG Oncology, Inc. Common stock Payout Ratio Analysis

CGON · NASDAQ
Dividends Paid
0.00
2025
Net Income
-161.00M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.